European regulators are accusing Johnson & Johnson of illegally paying another company to delay the availability of a generic version of a product – in the process denying cancer patients access to a less expensive source of a drug that eases severe pain.
According to a story in the New York Times, the product at issue is a transdermal patch used to deliver the drug fentanyl through the skin. Antitrust authorities ...
continue reading...
Johnson & Johnson appointed Andrew Ekdahl to head its orthopaedics division in 2011, a year after the company recalled its ASR artificial hip joints following thousands of complaints that they caused debilitating injuries.
According to the New York Times, the company had billed Ekdahl’s appointment as a fresh start.
The Times reports that Ekdahl had supervised the device’s introduction in the United ...
continue reading...
A story in The Telegraph says British members of parliament are calling for a criminal investigation into DePuy Orthopaedics, a division of Johnson & Johnson that manufactured “metal-on-metal” hip implants.
A Telegraph investigation found that DePuy continued to market the implants, which feature both a ball and socket coated in metal, after a leading British surgeon warned a company executive that they were causing read more.... --> continue reading...
An orthopedic surgeon testifying at a trial over Johnson & Johnson’s ASR hip implants described tissue colored black with metal debris around the hip joint as the “signature injury” of the devices.
According to a story in the Newark Star Ledger, Dr. Craig Swenson of La Jolla, Calif., refers to the blackened tissue around the artificial hip joints as the “black hole.”
The trial in Los Angeles is the first of 10,000 ...
continue reading...Johnson & Johnson’s earnings for the fourth quarter were better than expected, despite $800 million in expenses related to the company’s recall of its all-metal hip implant.
According to a story in Reuters, the company earned $1.19 per share, excluding one-time items, in the fourth quarter. That beat analysts’ average estimate of $1.17.
The story says the company faces about 2,000 lawsuits related to the “metal-on-metal” hip implant manufactured by Johnson & ...
continue reading...A 2011 internal report from Johnson & Johnson concluded that the company’s metal-on-metal hip implants would fail within five years in nearly 40 percent of patients, requiring them to undergo painful and costly replacement procedures.
A story in the New York Times says Johnson & Johnson recalled the device, made by subsidiary DePuy Orthopaedics, in 2010. Yet even as the company ...
continue reading...
